Helius Medical Technologies Faces Major Stock Drop and Changes
By ATTN Desk · Editorial oversight: Sean Han
Helius Medical Technologies, Inc. (Nasdaq: HSDT)
Introduction
Helius Medical Technologies, Inc. is a neurotechnology company based in Newtown, Pennsylvania. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), is a non-implantable, orally applied device designed to deliver mild electrical stimulation to the tongue. When paired with supervised therapeutic exercise, PoNS® is intended to promote neuroplasticity and improve balance and gait in patients with neurologic deficits.
Corporate Structure
- Headquarters: Newtown, Pennsylvania
- Industry: Medical Device (Neurotech)
- Employees: 11–50
- Listing: Nasdaq Capital Market (Ticker: HSDT)
- CIK: 0001610853
- Leadership: Dane Andreeff, President and Chief Executive Officer
Recent Developments and News
- May 12, 2025 – UnitedHealthcare approved reimbursement for PoNS® at a lump-sum rate of $18,100 (including patient co-payment), indicating expanded payer coverage for the device.
- April 30, 2025 – Board of Directors announced a 1-for-15 reverse stock split, effective May 1, 2025; trading on a split-adjusted basis began May 2, 2025 under the existing ticker HSDT.
- June 10, 2025 – Multiple Schedule 13G filings reported:
- CVI Investments, Inc. and Heights Capital Management, Inc. collectively own 183,450 shares (5.8%).
- Leonite Fund I, LP and Avi Geller own 163,055 shares (5.2%).
- FirstFire Global Opportunities Fund LLC holds 179,995 shares (5.7%).
Financial and Strategic Analysis
Key Stock and Market Metrics (as of 2025-06-12)
| Metric | Value |
|---|---|
| Share Price | $0.6236 |
| 1-Day % Change | –43.82% |
| Trading Volume | 3,029,686 |
| Market Capitalization | $586,097 |
| 52-Week Range | $0.7530–$24.00 |
| Average Volume (3 M) | 3,259,636 |
| Earnings Date | Aug 11–15, 2025 |
Recent Financial Results (TTM)
| Metric | Amount |
|---|---|
| Revenue | $434,000 |
| Net Income | –$13.06 M |
| Diluted EPS | –26.40 |
| Total Cash (mrq) | $1.11 M |
| Price/Sales | 0.75 |
| Price/Book | 0.46 |
| Return on Assets | –195.57% |
| Return on Equity | –800.00% |
- Liquidity and Balance Sheet: Cash reserves of $1.11 million with no reported debt.
- Valuation: The company's shares trade below book value and revenue, with no positive earnings reported.
- Strategic Moves:
- Reimbursement Approval (May 2025) supports the strategy for broadening patient access.
- Reverse Split (May 2025) was executed to meet Nasdaq listing requirements.
- Institutional Stakes: Three separate filings on June 10, 2025, indicate ownership by investment funds averaging approximately 5-6% each.
Market Position and Industry Context
- Product Authorization:
- United States: Approved for short-term treatment of gait deficits due to mild-to-moderate MS symptoms (adjunct to supervised exercise).
- Canada: Authorized for short-term treatment (14 weeks) of gait deficits due to stroke, traumatic brain injury, and MS (used alongside physical therapy).
- Australia: Approved for short-term use by healthcare professionals alongside exercise.
- Competitive Landscape: PoNS® operates within the neurostimulation segment of the medical device market, focusing on non-implantable platforms. Competitors include both implantable and non-implantable stimulator manufacturers.
- Industry Trends: There is growing interest in neuromodulation therapies for neurologic conditions, along with increasing emphasis on third-party reimbursement pathways.
tl;dr
- May 12, 2025: UnitedHealthcare approves $18,100 reimbursement for PoNS®.
- May 1–2, 2025: 1-for-15 reverse stock split takes effect; trading continues under HSDT.
- June 10, 2025: Three institutional investors file Schedule 13G, each holding approximately 5–6%.
- Share price on June 12, 2025: $0.6236 (–43.82%); Market Cap: $586,097; Cash: $1.11 million.
- Growth strategy: Focuses on expanded payer coverage and compliance with listing requirements.